beeldscherm schreef op 29 september 2017 13:09:
it is interesting to note that Pharming contributed, many years ago, to the development of Genzyme’s (now Sanofi’s) blockbuster product Cerezyme for the treatment of Pompe disease that generated $914 million of sales in 2013 — another lucrative market in which Pharming has experience and the potential to develop an effective, competitive product.
Other ongoing developments also include ongoing preclinical research — exclusively led, financed and managed by third parties including the US Army — about Ruconest’s promising effects in Ischemia/Reperfusion Injury (IRI)prevention in organ transplants, delayed graft function and hemorrhagic shock